Corbus Pharmaceuticals Holdings, Inc. (CRBP) Fair Value 2026

CRBP · Biotechnology · 2026-08-28

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-28, Corbus Pharmaceuticals Holdings, Inc. (CRBP) trades at $10.91. QOC: 4.3/10. Value Trap Risk: 35/100 (LOW). 0/13 models active.

Key Facts

Ticker: CRBP
Price: $10.91
Quality Score: 4.3/10
Value Trap Risk: 35/100
Models Active: 0/13
Last Updated: 2026-08-28

Strength: 0 independent models provide multi-angle coverage

Risk: Below-average Quality Score of 4.3/10 signals weak fundamentals

What Fair Value Does Each Model Give CRBP?

0 Intrinsic Value Models vs. Current Price ($10.91)

Core Models (Unlocked)
Model	Fair Value	Upside

All Models Active

All 0 models are displayed above.

What Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Corbus Pharmaceuticals Holdings, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About CRBP?

0 of 13 models are currently active for CRBP. See which stocks rank higher →

How Does CRBP Rank in Biotechnology?

Among 625 Biotechnology stocks, CRBP ranks #496 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Corbus Pharmaceuticals Holdings, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CRBP a Value Trap?

CirclFi's Value Trap algorithm assigns CRBP a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Corbus Pharmaceuticals Holdings, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Corbus Pharmaceuticals Holdings, Inc. is rated at 4.3/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CRBP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Corbus Pharmaceuticals Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ENVBEnveric Biosciences, Inc.QOC 4.3 DCOYDecoy Therapeutics Inc.QOC 4.3 CLDICalidi Biotherapeutics, Inc.QOC 4.3 PASGPassage Bio, Inc.QOC 4.3 FBRXForte Biosciences, Inc.QOC 4.3 INDPIndaptus Therapeutics, Inc.QOC 4.3 TGTXTG Therapeutics, Inc.QOC 8.1 TRDAEntrada Therapeutics, Inc.QOC 5.7 SRZNSurrozen, Inc.QOC 4.9 EXELExelixis, Inc.QOC 9.6 INCYIncyte CorporationQOC 9.5

Read investment analysis: ENVB · DCOY · CLDI · PASG · FBRX · INDP · TGTX · TRDA · SRZN · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CRBP?

6 companies across all industries closest to CRBP’s Quality of Company score of 4.3/10.

LTUMLithium CorporationQOC 4.3 COBACHILEAN COBALT CORP.QOC 4.3 KRFGKing Resources, IncQOC 4.3 ONFOOnfolio Holdings, Inc.QOC 4.3 FCCIEyeonix AIQ, Inc.QOC 4.3 NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LTUM · COBA · KRFG · ONFO · FCCI · NVDA

Where Does CRBP Sit in CirclFi's Biotechnology Rankings?

CRBP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Corbus Pharmaceuticals Holdings, Inc.’s Valuation?

What is Corbus Pharmaceuticals Holdings, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Corbus Pharmaceuticals Holdings, Inc. (CRBP). The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CRBP overvalued or undervalued right now?

At $10.91, 0 of 0 active models suggest CRBP may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Corbus Pharmaceuticals Holdings, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.3 mean for CRBP?

Corbus Pharmaceuticals Holdings, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CRBP?

CirclFi analyzes CRBP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is CRBP a value trap in 2026?

Corbus Pharmaceuticals Holdings, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Corbus Pharmaceuticals Holdings, Inc. (CRBP) a Quality of Company score of 4.3/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CRBP/ · Methodology

Primary sources for this CRBP valuation

Financial statements: Corbus Pharmaceuticals Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001595097) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CRBP as of 2026-08-28; valuations recomputed 2026-08-28.